CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 12.6%

CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) shares shot up 12.6% during trading on Tuesday . The stock traded as high as $48.66 and last traded at $48.66. 157,686 shares changed hands during trading, a decline of 90% from the average session volume of 1,519,679 shares. The stock had previously closed at $43.23.

Several brokerages have weighed in on CRSP. Stifel Nicolaus lowered their target price on CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. Oppenheimer cut their price target on CRISPR Therapeutics from $172.00 to $150.00 in a report on Wednesday. Credit Suisse Group began coverage on CRISPR Therapeutics in a report on Thursday, April 28th. They issued a “neutral” rating and a $78.00 price target for the company. SVB Leerink dropped their target price on CRISPR Therapeutics from $126.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, February 16th. Finally, Chardan Capital reduced their price target on shares of CRISPR Therapeutics from $171.00 to $168.00 in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $122.36.

The stock has a market cap of $3.60 billion, a P/E ratio of 10.85 and a beta of 2.05. The firm’s fifty day moving average is $59.51 and its 200 day moving average is $68.70.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.38). The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $2.45 million. CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. The firm’s revenue for the quarter was up 74.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.51) EPS. Equities research analysts anticipate that CRISPR Therapeutics AG will post -7.69 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. HighTower Advisors LLC lifted its holdings in CRISPR Therapeutics by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 43,159 shares of the company’s stock valued at $4,830,000 after purchasing an additional 2,906 shares during the last quarter. Brave Asset Management Inc. grew its position in shares of CRISPR Therapeutics by 40.0% during the 4th quarter. Brave Asset Management Inc. now owns 3,500 shares of the company’s stock valued at $265,000 after purchasing an additional 1,000 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in CRISPR Therapeutics by 16.8% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 1,238 shares of the company’s stock worth $94,000 after purchasing an additional 178 shares during the last quarter. Concord Wealth Partners increased its holdings in CRISPR Therapeutics by 277.3% during the 4th quarter. Concord Wealth Partners now owns 796 shares of the company’s stock valued at $60,000 after purchasing an additional 585 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of CRISPR Therapeutics by 19.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 116,485 shares of the company’s stock worth $13,038,000 after purchasing an additional 19,343 shares in the last quarter. 56.12% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.